Evercore ISI has upgraded Cardinal Health (NYSE:CAH) to outperform from in line, citing the company's improved outlook. The investment firm said it sees FY'25 pharma AOI guidance as conservative, with upside to the company's long-term guidance.

BofA has upgraded Cardinal Health (NYSE:CAH) to buy from neutral, citing accelerating growth. "Cardinal’s (NYSE:CAH) organic growth in the core pharma segment has begun to outpace peers and this is likely to become more pronounced over the next year,